Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Harvard Business School
Mallinckrodt
McKinsey
AstraZeneca
Express Scripts
McKesson

Last Updated: February 25, 2020

DrugPatentWatch Database Preview

Details for Patent: 7,964,202


Email this page to a colleague

See Plans and Pricing

« Back to Dashboard

Which drugs does patent 7,964,202 protect, and when does it expire?

Patent 7,964,202 protects EPIDUO and is included in one NDA.

This patent has thirty-three patent family members in twenty-two countries.

Summary for Patent: 7,964,202
Title:Method for treatment of common acne
Abstract: Dermatological/cosmetic compositions suited for preventing or treating cell differentiation and/or proliferation and/or keratinization disorders, including preventing or treating common acne, comprise, in a physiologically acceptable medium, (i) at least one dispersed retinoid, (ii) dispersed benzoyl peroxide, in free or encapsulated form, and (iii) at least one pH-independent gelling agent, said dermatological/cosmetic composition having physical stability without loss of viscosity over time at a temperature ranging from 4.degree. C. to 40.degree. C., said dermatological/cosmetic composition having a stable flow threshold over time as measured by viscosity measurements for rheograms which measure a shear stress .tau. for a given rate gradient .gamma. and which measure a rate gradient .gamma. for a given shear stress .tau., the yield value (.tau.0) being extrapolated visually or by calculation.
Inventor(s): Orsoni; Sandrine (Mandelieu, FR), Willcox; Nathalie (Le Rouret, FR)
Assignee: Galderma Research & Development, S.N.C. (FR)
Application Number:12/076,859
Patent Claim Types:
see list of patent claims
Use; Composition;

Drugs Protected by US Patent 7,964,202

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Galderma Labs Lp EPIDUO adapalene; benzoyl peroxide GEL;TOPICAL 022320-001 Dec 8, 2008 AB RX Yes Yes   Start Trial   Start Trial Y TREATMENT OF ACNE   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 7,964,202

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
France01 16747Dec 21, 2001

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Baxter
Boehringer Ingelheim
Moodys
Mallinckrodt
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.